​

Boundless Bio (BOLD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

BOLD Stock Rating

Boundless Bio stock's rating consensus is Hold, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (45.00%), 10 Hold (50.00%), 1 Sell (5.00%), and 0 Strong Sell (0.00%).

Hold
Total 20 0 1 10 9 Strong Sell Sell Hold Buy Strong Buy

BOLD Price Target Upside V Benchmarks

TypeNameUpside
StockBoundless Bio-
SectorHealthcare Stocks 19.91%
IndustryBiotech Stocks 55.52%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.19$1.19$1.19
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 251-2--3
Jun, 251-2--3
May, 25-11--2
Apr, 25-11--2
Mar, 25111--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.85----
Avg Forecast$-6.54$-3.47$-3.74$-5.76$-6.24
High Forecast$-6.46$-3.43$-3.74$-5.76$-6.24
Low Forecast$-6.63$-3.50$-3.74$-5.76$-6.24
Surprise %-41.13%----

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-----
Avg Forecast----$8.40M
High Forecast----$8.40M
Low Forecast----$8.40M
Surprise %-----

Net Income Forecast

$-150M $-133M $-116M $-99M $-82M $-65M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-65.36M----
Avg Forecast$-145.50M$-77.06M$-83.23M$-128.10M$-138.77M
High Forecast$-143.61M$-76.22M$-83.23M$-128.10M$-138.77M
Low Forecast$-147.39M$-77.90M$-83.23M$-128.10M$-138.77M
Surprise %-55.08%----

BOLD Forecast FAQ

Is Boundless Bio stock a buy?

Boundless Bio stock has a consensus rating of Hold, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 10 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Boundless Bio is a neutral investment for most analysts.

What is Boundless Bio's price target?

Boundless Bio's price target, set by 20 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.19.

How does Boundless Bio stock forecast compare to its benchmarks?

Boundless Bio's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (19.91%) and underperforming the biotech stocks industry (55.52%).

What is the breakdown of analyst ratings for Boundless Bio over the past three months?

  • July 2025: 33.33% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 33.33% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Boundless Bio’s EPS forecast?

Boundless Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.47, marking a -9.87% decrease from the reported $-3.85 in 2024. Estimates for the following years are $-3.74 in 2026, $-5.76 in 2027, and $-6.24 in 2028.

What is Boundless Bio’s revenue forecast?

Boundless Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $0 for 2027, and $8.4M for 2028.

What is Boundless Bio’s net income forecast?

Boundless Bio's net income forecast for the fiscal year ending in December 2025 stands at $-77.059M, representing an 17.89% increase from the reported $-65.363M in 2024. Projections indicate $-83.231M in 2026, $-128M in 2027, and $-139M in 2028.